Midaflur
Chemical compound
- None
- 2,2,5,5-Tetrakis(trifluoromethyl)-2,5-dihydro-1H-imidazol-4-amine
- 23757-42-8
- 32068
- 29737
- 840CTL676L
- D05027
- ChEMBL2104707
- DTXSID50178425
- Interactive image
- C1(=NC(NC1(C(F)(F)F)C(F)(F)F)(C(F)(F)F)C(F)(F)F)N
InChI
- InChI=1S/C7H3F12N3/c8-4(9,10)2(5(11,12)13)1(20)21-3(22-2,6(14,15)16)7(17,18)19/h22H,(H2,20,21)
- Key:KYWMWUUMCDZISK-UHFFFAOYSA-N
Midaflur (INN; EXP 338) is an extremely stable 3-imidazoline derivative with central skeletal muscle relaxant and sedative properties in humans[1] and other species of mammals, exhibiting consistently high oral bioavailability and a long duration of action. While its pharmacodynamics remain poorly understood, midaflur resembles meprobamate and pentobarbital in terms of observed effects while being considerably more potent.[2]
See also
- Propofol
- Pentobarbital
References
- ^ Levine IM, Jossmann PB, Friend DG, DeAngelis V (1967). "Effect of 5-imino-2,2,4,4-tetrakis (trifluoromethyl) imidazolidine (EXP 338) on spasticity: A quantitative evaluation". Clinical Pharmacology and Therapeutics. 9 (4): 448–55. doi:10.1002/cpt196894448. PMID 4871898. S2CID 39263140.
- ^ Clark R, Lynes TE, Price WA, Smith DH, Woodward JK, Marvel JP, Vernier VG (April 1971). "The pharmacology and toxicology of midaflur". Toxicology and Applied Pharmacology. 18 (4): 917–43. doi:10.1016/0041-008x(71)90239-0. PMID 5570243.
- v
- t
- e
| Phenols | |
|---|---|
| Barbiturates | |
| Benzodiazepines | |
| Opioids | |
| Arylcyclohexylamines | |
| Neuroactive steroids | |
| Others |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
